| Mun Conners Guthmiller, NURSE ANESTHETIST | |
|
433 East Santa Clara St, Arcadia, CA 91006 | |
| (702) 651-2274 | |
| Not Available |
| Full Name | Mun Conners Guthmiller |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 16 Years |
| Location | 433 East Santa Clara St, Arcadia, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245433549 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | CA616826 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Burbank Anesthesia Associates A Professional Medical Corporation | 3577832187 | 2 |
| Amsurg South Bay Anesthesia Lp | 4082853411 | 17 |
| Southern California Permanente Medical Group | 6002729175 | 7951 |
| Amsurg Arcadia Anesthesia Lp | 7214199850 | 7 |
News Archive
A Finnish team of researchers was the first in the world to discover a gene mutation in ameloblastoma, which is a tumour of the jaw.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
The current study reveals that mice infected with mycobacterium tuberculosis are resistant to SARS-CoV-2 infection.
The Behavioral Science Lab has released the second paper in their insights series, "Cracking the Code on Why We Give to Charities."
› Verified 8 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
A Finnish team of researchers was the first in the world to discover a gene mutation in ameloblastoma, which is a tumour of the jaw.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
The current study reveals that mice infected with mycobacterium tuberculosis are resistant to SARS-CoV-2 infection.
The Behavioral Science Lab has released the second paper in their insights series, "Cracking the Code on Why We Give to Charities."
› Verified 8 days ago
| Entity Name | Advanced Anesthesia Specialists A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871733600 PECOS PAC ID: 0042340705 Enrollment ID: O20100608000088 |
News Archive
A Finnish team of researchers was the first in the world to discover a gene mutation in ameloblastoma, which is a tumour of the jaw.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
The current study reveals that mice infected with mycobacterium tuberculosis are resistant to SARS-CoV-2 infection.
The Behavioral Science Lab has released the second paper in their insights series, "Cracking the Code on Why We Give to Charities."
› Verified 8 days ago
| Entity Name | Amsurg Arcadia Anesthesia Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114291226 PECOS PAC ID: 7214199850 Enrollment ID: O20120427000249 |
News Archive
A Finnish team of researchers was the first in the world to discover a gene mutation in ameloblastoma, which is a tumour of the jaw.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
The current study reveals that mice infected with mycobacterium tuberculosis are resistant to SARS-CoV-2 infection.
The Behavioral Science Lab has released the second paper in their insights series, "Cracking the Code on Why We Give to Charities."
› Verified 8 days ago
| Entity Name | Amsurg South Bay Anesthesia Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811230022 PECOS PAC ID: 4082853411 Enrollment ID: O20130617000101 |
News Archive
A Finnish team of researchers was the first in the world to discover a gene mutation in ameloblastoma, which is a tumour of the jaw.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
The current study reveals that mice infected with mycobacterium tuberculosis are resistant to SARS-CoV-2 infection.
The Behavioral Science Lab has released the second paper in their insights series, "Cracking the Code on Why We Give to Charities."
› Verified 8 days ago
| Entity Name | Burbank Anesthesia Associates A Professional Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699201723 PECOS PAC ID: 3577832187 Enrollment ID: O20170712003380 |
News Archive
A Finnish team of researchers was the first in the world to discover a gene mutation in ameloblastoma, which is a tumour of the jaw.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
The current study reveals that mice infected with mycobacterium tuberculosis are resistant to SARS-CoV-2 infection.
The Behavioral Science Lab has released the second paper in their insights series, "Cracking the Code on Why We Give to Charities."
› Verified 8 days ago
| Entity Name | Tower Anesthesia Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407370901 PECOS PAC ID: 3375815723 Enrollment ID: O20170818001842 |
News Archive
A Finnish team of researchers was the first in the world to discover a gene mutation in ameloblastoma, which is a tumour of the jaw.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
The current study reveals that mice infected with mycobacterium tuberculosis are resistant to SARS-CoV-2 infection.
The Behavioral Science Lab has released the second paper in their insights series, "Cracking the Code on Why We Give to Charities."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mun Conners Guthmiller, NURSE ANESTHETIST 2830 Somerset Pl, San Marino, CA 91108-3032 Ph: (210) 573-3897 | Mun Conners Guthmiller, NURSE ANESTHETIST 433 East Santa Clara St, Arcadia, CA 91006 Ph: (702) 651-2274 |
News Archive
A Finnish team of researchers was the first in the world to discover a gene mutation in ameloblastoma, which is a tumour of the jaw.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
The current study reveals that mice infected with mycobacterium tuberculosis are resistant to SARS-CoV-2 infection.
The Behavioral Science Lab has released the second paper in their insights series, "Cracking the Code on Why We Give to Charities."
› Verified 8 days ago